RSPI (RespireRx Pharmaceuticals) GF Score: 12/100 (As of Jul. 10, 2026) — 57% Below Median


RSPI RespireRx Pharmaceuticals Inc RSPI
12 GF Score
Price $0.00
View Full Analysis

What is RespireRx Pharmaceuticals GF Score?

RespireRx Pharmaceuticals RSPI 12 GF Score is 12 as of Jul. 10, 2026, which is 57% below its 10-year median of 28.00. GuruFocus rates RSPI with a GF Score™ of 12/100.

RespireRx Pharmaceuticals has the GF Score of 12, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 0/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes RespireRx Pharmaceuticals might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

RespireRx Pharmaceuticals  (OTCPK:RSPI) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

RespireRx Pharmaceuticals GF Score Related Terms

RSPI vs CNBX, NAVB, IPIX: GF Score Comparison

For the Biotechnology subindustry, RespireRx Pharmaceuticals's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RespireRx Pharmaceuticals GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RespireRx Pharmaceuticals's GF Score distribution charts can be found below:

* The bar in red indicates where RespireRx Pharmaceuticals's GF Score falls into.


RSPI
12GF Score
RespireRx Pharmaceuticals Inc RSPI
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 12 mean?
RespireRx Pharmaceuticals (RSPI) has a GF Score of 12 as of Jul. 10, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on RespireRx Pharmaceuticals and its competitors. This is 57% below median its historical median of 28.00. Over the past decade, RespireRx Pharmaceuticals' GF Score has ranged from 12.00 to 36.00.
Is RespireRx Pharmaceuticals' GF Score too high?
RespireRx Pharmaceuticals' current GF Score of 12 is 57% below median its 10-year median of 28.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 36.00. Overall, RespireRx Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does RespireRx Pharmaceuticals' GF Score compare to CNBX and NAVB?
RespireRx Pharmaceuticals' GF Score of 12 can be compared against companies in the Biotechnology industry. Historically, RespireRx Pharmaceuticals' own GF Score has ranged from 12.00 to 36.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on RespireRx Pharmaceuticals and its competitors. RespireRx Pharmaceuticals's current GF Score is 12, which is 57% below median its own 10-year median of 28.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RespireRx Pharmaceuticals stock overvalued right now?
RespireRx Pharmaceuticals (RSPI) has a current GF Score of 12. The current GF Score is 12, which is 57% below median its 10-year median of 28.00. RespireRx Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For RespireRx Pharmaceuticals (RSPI), the current GF Score is 12 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RespireRx Pharmaceuticals Business Description

Address 126 Valley Road, Suite C, Glen Rock, NJ, USA, 07452
RespireRx Pharmaceuticals Inc is engaged in the discovery, value-added development, and commercialization through partners of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is in a 505(b)(2) development ideas for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; AMPAkines CX1739 for the treatment of bladder control and other conditions associated with spinal injury; CX717 for ADHD and CX1942 which is an injectable dosage formulation and GABAkines lead KRM-II-81 in preclinical development for treatment resistant epilepsy and non-opioid pain management.
12GF Score

Get the complete analysis for RSPI

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price